MK-6837
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MK-6837, covering 2025-12-31 to 2025-12-31. Get the full timeline:
Most recent: Clinical Trial Update: A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001) [Phase 1]